Dr. Rini on the Axitinib and Sorafenib Trial VEGF Focus

Brian I. Rini, MD
Published: Friday, Jul 01, 2011

Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio, explains the vascular enthothelial growth factor (VEGF) potency and comparison explored in the AXIS 1032 phase III trial comparing axitinib to sorafenib (both VEGF inhibitors) in the second-line setting for metastatic renal cell carcinoma (mRCC).

Dr. Rini says many doctors had a hypothesis that the agents that are more potent and selective against the VEGF receptor family, which is the major therapeutic receptor in kidney cancer, would produce clinical benefits. Up until now, there was no comparative data to support or refute that hypothesis. The AXIS 1032 phase III trial study, by in essence comparing a more potent versus a less potent VEGF inhibitor, provides data to say there is a clinical advantage to that biochemical drug advantage. Dr. Rini adds that other studies with other settings and other drugs are needed to flesh out the story, but the theme is becoming clearer as more clinical data is collected.
Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at Cleveland Clinic in Ohio, explains the vascular enthothelial growth factor (VEGF) potency and comparison explored in the AXIS 1032 phase III trial comparing axitinib to sorafenib (both VEGF inhibitors) in the second-line setting for metastatic renal cell carcinoma (mRCC).

Dr. Rini says many doctors had a hypothesis that the agents that are more potent and selective against the VEGF receptor family, which is the major therapeutic receptor in kidney cancer, would produce clinical benefits. Up until now, there was no comparative data to support or refute that hypothesis. The AXIS 1032 phase III trial study, by in essence comparing a more potent versus a less potent VEGF inhibitor, provides data to say there is a clinical advantage to that biochemical drug advantage. Dr. Rini adds that other studies with other settings and other drugs are needed to flesh out the story, but the theme is becoming clearer as more clinical data is collected.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections: New York GU™: 10th Annual Interdisciplinary Prostate Cancer Congress® and other Genitourinary MalignanciesMay 30, 20181.5
Community Practice Connections™: Advancing RCC: A Focused Assessment of Recent Paradigm Shifts and Next Steps to Move the Field ForwardMay 30, 20181.5
Publication Bottom Border
Border Publication
x